Dr Reddy's Flags Semaglutide Supply Delay After API Issue; Stock Falls Nearly 6%

Dr. Reddy's Laboratories has announced a delay in the commercial supply of its semaglutide drug after identifying an issue with the active pharmaceutical ingredient (API) in certain batches. In this video, Neetu Chandra Sharma, Business Today explains what led to the delay, the company's ongoing investigation, and the corrective measures being taken. Dr. Reddy's has clarified that there is no impact on patient safety and no effect on its existing global regulatory filings. The update has, however, weighed on investor sentiment, sending the stock lower.